Bronwen Garner, MD
Infectious Disease · Atlanta, GANPI 1588954796
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 63 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$187
- Boehringer Ingelheim$150
- Abbott$137
- Merck$128
- Cepheid$123
- Pfizer$106
- plus $592 from 19 others
Across 7 payments — averaging $3381.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nobelpharma America, LLC$24K
What the payments were for
- Food & beverage$1,424100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENEXPERT$123
How this compares
$1,424 in reported general payments places this provider in the 55th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Itraconazole | 13 | $21,298 |
| Daptomycin | 40 | $18,921 |
| CeftriaxoneCeftriaxone Sodium | 51 | $13,250 |
| Ampicillin Sodium | 63 | $12,734 |
| Posaconazole | 11 | $12,155 |
| Fosfomycin Tromethamine | 28 | $11,892 |
| MicafunginMicafungin Sodium | 24 | $10,274 |
| Meropenem | 33 | $9,106 |
| Methenamine Hippurate | 104 | $7,851 |
| Fluconazole | 15 | $1,142 |
| Doxycycline Hyclate | 24 | $1,041 |
| Cephalexin | 31 | $799 |
| Ciprofloxacin Hcl | 20 | $773 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $196 |
| Levofloxacin | 18 | $190 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Atlanta
- Zandraetta Tims-CookAtlanta$848K
- Larry AndersonAtlanta$300K
- Quintin RobinsonAtlanta$270K
- James McMillenAtlanta$177K
- Leandro MenaAtlanta$141K
- Colleen KraftAtlanta$103K
- Walter OrensteinAtlanta$78K
- Nadine RouphaelAtlanta$66K
- Kimberly WorkowskiAtlanta$53K
- Bernard BransonAtlanta$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.